Atara Biotherapeutics Inc (ATRA) was Downgraded by Goldman to ” Sell”. Earlier the firm had a rating of “Neutral ” on the company shares. Goldman advised their investors in a research report released on Sep 15, 2016.
On the company’s financial health, Atara Biotherapeutics Inc reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on May 5, 2016. Analyst had a consensus of $-0.60.During the same quarter in the previous year, the company posted $-0.42 EPS.
Atara Biotherapeutics Inc opened for trading at $21.13 and hit $22.03 on the upside on Wednesday, eventually ending the session at $21.33, with a gain of 1.81% or 0.38 points. The heightened volatility saw the trading volume jump to 86,577 shares. Company has a market cap of $615 M.
In a different news, on Aug 23, 2016, Isaac E. Ciechanover (Chief Executive Officer) sold 9,600 shares at $22.33 per share price. According to the SEC, on Aug 17, 2016, Christopher Haqq (Chief Medical Officer) sold 1,346 shares at $22.14 per share price. On Aug 17, 2016, Gad Soffer (Chief Operating Officer) sold 5,356 shares at $21.69 per share price, according to the Form-4 filing with the securities and exchange commission.
Atara Biotherapeutics Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics for serious unmet medical needs with an initial focus on muscle wasting conditions and oncology. The Company’s lead product candidate PINTA 745 is a peptibody that binds myostatin and inhibits its corresponding signal transduction thereby blocking the negative regulation of skeletal muscle growth. PINTA 745 is in a Phase II clinical trial. The Company’s second product candidate STM 434 which is in a Phase I clinical study is a soluble ActR2B receptor that binds Activin A. The Company has five additional product candidates: ATA 842 a humanized antibody targeting myostatin; ATA 777 a fully human antibody targeting Activin A; ATA M43 a fully human anti-ActR2A/2B monoclonal antibody; STM 217 a soluble ActR2B receptor-IgG Fc fusion protein and a close analog of STM 434 and ActR2B5 a soluble ActR2B receptor that can be fused to an IgG Fc receptor.